Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 12 points (0.1%) at 17,830 as of Tuesday, Nov. 25, 2014, 12:15 PM ET. The NYSE advances/declines ratio sits at 1,420 issues advancing vs. 1,510 declining with 216 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include

Receptos

(

RCPT

), down 5.2%,

Incyte

(

INCY

), down 2.1%,

Pharmacyclics

(

PCYC

), down 2.0%,

Alexion Pharmaceuticals

(

ALXN

), down 0.8% and

AstraZeneca

(

AZN

), down 0.3%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Vertex Pharmaceuticals

(

VRTX

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $0.46 (0.4%) to $114.26 on light volume. Thus far, 433,540 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $113.63-$114.99 after having opened the day at $114.17 as compared to the previous trading day's close of $113.80.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $26.8 billion and is part of the health care sector. Shares are up 49.9% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Vertex Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full

Vertex Pharmaceuticals Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is up $2.02 (1.4%) to $144.58 on light volume. Thus far, 609,439 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $140.87-$144.65 after having opened the day at $142.96 as compared to the previous trading day's close of $142.56.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $48.8 billion and is part of the health care sector. Shares are up 21.4% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Actavis

(

ACT

) is up $2.97 (1.1%) to $269.85 on average volume. Thus far, 1.7 million shares of Actavis exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $266.57-$271.39 after having opened the day at $267.15 as compared to the previous trading day's close of $266.88.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $68.8 billion and is part of the health care sector. Shares are up 58.9% year-to-date as of the close of trading on Monday. Currently there are 15 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Actavis

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Actavis Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null